Publications by authors named "Louise Sheridan"
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or previously treated mantle cell lymphoma. As the bioavailability of the acalabrutinib capsule (AC) depends on gastric pH for solubility and is impaired by acid-suppressing therapies, coadministration with proton-pump inhibitors (PPIs) is not recommended. Three studies in healthy subjects (N = 30, N = 66, N = 20) evaluated the pharmacokinetics (PKs), pharmacodynamics (PDs), safety, and tolerability of acalabrutinib maleate tablet (AT) formulated with pH-independent release.
View Article and Find Full Text PDFArticle Synopsis
- Acalabrutinib is a drug used for certain types of blood cancers and is affected by proton-pump inhibitors (PPIs), which reduce its absorption when taken together.
- A study was conducted to compare the bioavailability of acalabrutinib delivered via nasogastric (NG) tube using a Coca-Cola suspension versus the oral capsule and to assess the PPI's effect.
- The results showed that the absorption of acalabrutinib was similar for both NG and oral delivery methods, with no safety issues, indicating that acalabrutinib can be safely administered with or without PPIs.